ROR1 and breast carcinoma: Targeting ROR1 by small molecules and mAbs has been shown to be an effective therapeutic approach in pre-clinical and clinical studies in various malignancies, such as CLL, MCL, lung, breast cancers, etc. [27,43,46,67,71].